Betterlife Pharma Inc. · CSE:BETR

Betterlife Pharma — Investor Presentation (July 2026)

18 slides from Betterlife Pharma's investor presentation, July 2026

  1. Slide 1: BETR-001: Non-hallucinogenic neuroplastogen for migraine and headache disorders

    BetterLife Pharma Inc. BETR-001 Non-hallucinogenic neuroplastogen for migraine and headache disorders July 2026 CSE: BETR OTC: BETRF 1

  2. Slide 2: Disclaimer

    Disclaimer This presentation may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. BetterLi

  3. Slide 3: Investment Highlights

    Investment Highlights BetterLife Pharma Inc. is developing BETR-001 as a potential disease modifying treatment for migraine and other headache disorders  BETR-001 is a novel non-hallucinogenic neuroplastogen that isolates the pharmacologically active 6R:9R stereoisomer of 2-bromo-LSD  Historic stu

  4. Slide 4: Migraine: Mega-Blockbuster Indication that Remains Poorly Treated

    Migraine: Mega-Blockbuster Indication that Remains Poorly Treated 1B+ $9B 50%+ Opportunities within other headache Migraine patients globally Current global migraine Migraine patients ~40M in the U.S. alone1 drug market, 9% CAGR2 remain refractory3 disorders Migraine Prevention Cluster Headache The

  5. Slide 5: Psychedelics: A Potential Disease Modifying Class for Migraine

    Psychedelics: A Potential Disease Modifying Class for Migraine Classic psychedelics have shown remarkable efficacy in migraine, but safety concerns and hallucinations prevent broad adoption Evidence of Efficacy Barriers to Adoption  Case series and uncontrolled studies spanning five decades suggest

  6. Slide 6: BETR-001 Benefits from Decades of Human Data with 2-Bromo-LSD

    BETR-001 Benefits from Decades of Human Data with 2-Bromo-LSD The most extensively characterized non-hallucinogenic psychedelic analog, now optimized to maximize therapeutic benefit 1955 1960s 2010 2020s Human studies Shown to block LSD-induced Karst et al. landmark study THE INNOVATION demonstrate

  7. Slide 7: 2-Bromo-LSD Has Shown Rapid and Durable Headache Remission

    2-Bromo-LSD Has Shown Rapid and Durable Headache Remission Early efficacy in notoriously refractory cluster headaches paves the way for expansion into migraine  Racemic 2-bromo-LSD (coded as BOL-148) led to durable remission in cluster headache, with response extending throughout the 16-week monito

  8. Slide 8: The Solution: BETR-001 as a Disease Modifying Migraine Therapy

    The Solution: BETR-001 as a Disease Modifying Migraine Therapy BETR-001’s receptor activity combines the mechanisms of triptans, ditans, ergolines and psychedelics, all in one molecule What Was Discovered BETR-001 6R:9R stereoisomer of 2- bromo-LSD is the most active stereoisomer Ergolines & Triptan

  9. Slide 9: BETR-001 Has the Key Features for True Disease Modification

    BETR-001 Has the Key Features for True Disease Modification BETR-001 hits the key receptors needed for migraine efficacy, promotes neuroplasticity and does not induce tolerance, giving it a differentiated mechanism BETR-001 Causes Limited 5-HT2A BETR-001: BETR-001 is a Potent Receptor Internalizatio

  10. Slide 10: Validation from Other Therapies Using Same Ergoline Scaffold

    Validation from Other Therapies Using Same Ergoline Scaffold Showed strong clinical efficacy but also tox liabilities BETR-001 retains the validated serotonergic mechanism while engineering out each predecessor's safety liability Sample longitudinal patient data demonstrating reduction in cluster he

  11. Slide 11: BETR-001 is Significantly Differentiated from Alternative Therapies

    BETR-001 is Significantly Differentiated from Alternative Therapies Ergolines BETR-001 Psychedelics CGRP mAbs (DHE, Methysergide) Disease-Modifying Yes No Yes No Potential Hallucinogenic No No Yes No 5-HT2B agonism No Yes Yes No Cardiac Risk Scheduling Rx Rx Schedule I Rx Administration Oral, at-hom

  12. Slide 12: BETR-001 has a Robust Intellectual Property Position

    BETR-001 has a Robust Intellectual Property Position Composition of Matter Proprietary Synthesis Method of Use (US 12,331,051) (US 9,868,732; US 10,377,752) (US2024/0058326A1; WO2023/044573A1) Protection until 2042 Protection until 2036 Protection until 2041 • Patent protection based on the • Novel

  13. Slide 13: BETR-001 Development Plan: Phase 1B with PoC Readout

    BETR-001 Development Plan: Phase 1B with PoC Readout in ≈ 30 months 8 Months 9–12 Months 12–18 Months ≈36 Months Completion of IND- PRECLINICAL enabling Studies MANUFACTURING Clinical Trial Supply CLINICAL - Phase 1B: IND Phase 1A: Phase 2/3: REGULATORY Healthy Volunteers Migraine Migraine / Cluster

  14. Slide 14: Significant Indication Expansion Potential Across Neuropsychiatry

    Significant Indication Expansion Potential Across Neuropsychiatry Substantiated by ergoline clinical history, psychedelic Phase 3 data, and BETR-001 preclinical signals In Development Preclinical Data Treatment-Resistant Migraine Depression ~4M severe US patients 1 Ergoline class efficacy proven wit

  15. Slide 15: Migraine: Attractive Deal Precedents

    Migraine: Attractive Deal Precedents Big pharma is seeking innovation in this space $13B Total Deal Value (2022) $2B Total Deal Value (2019) Driven by Nurtec ODT (first approved oral CGRP blocker) and Driven by the late-stage anti-CGRP antibody, eptinezumab, being Zavegepant (intranasal CGRP blocker

  16. Slide 16: Team and Advisors

    Team and Advisors  100+ years combined pharma leadership experience across drug development, regulatory, and commercialization  Team and advisory board expanding as BetterLife advances to clinical stage Ahmad Doroudian, PhD Douglas Drysdale Hooshmand CEO & Director Executive Chairman & Director Sh

  17. Slide 17: BETR-001 Summary

    BETR-001 Summary The only non-hallucinogenic neuroplastogen in development for migraine and other headache disorders, a large and underserved market with no disease-modifying options Differentiated • Disease modification potential supported by strong efficacy and safety seen with racemic 2- Mechanis

  18. Slide 18: Ahmad Doroudian, Doug Drysdale

    Ahmad Doroudian ahmad.doroudian@blifepharma.com Doug Drysdale DDrysdale@blifepharma.com 18

BetterLife Pharma — Investor Presentation (July 2026) on 6ix